Novo Nordisk CFO Karsten Munk Knudsen joins “The Top Line” to discuss oral Wegovy’s rollout, the company’s raised outlook, why he’s still optimistic about CagriSema and more.
Novo Nordisk CFO Karsten Munk Knudsen joins “The Top Line” to discuss oral Wegovy’s rollout, the company’s raised outlook, why he’s still optimistic about CagriSema and more.